Latest news with #AurobindoPharmaLtd.
Economic Times
6 days ago
- Business
- Economic Times
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to Add (from Buy earlier) with a revised target price of Rs 1,330 (earlier Rs 1,445). The current market price of Aurobindo Pharma Ltd. is Rs 1147.95. Aurobindo Pharma, incorporated in 1986, is a Large Cap company with a market cap of Rs 66664.41 crore, operating in the Pharmaceuticals sector. ADVERTISEMENT Aurobindo Pharma's key products/revenue segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2024. Financials For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 8516.93 crore, up 4.68 % from last quarter Total Income of Rs 8135.81 crore and up 10.38 % from last year same quarter Total Income of Rs 7715.77 crore. The company has reported net profit after tax of Rs 935.02 crore in the latest quarter. The company's top management includes Mr.M Ramasubramanian Kumar, Mukherjee, Mahajan, P Vanvari, Mr.P Sarath Chandra Reddy, Makkapati, Mr.P V Ramprasad Reddy, Mr.M Madan Mohan Reddy, Mr.K Nithyananda Reddy, Pant Joshi. Company has Deloitte Haskins & Sells as its auditors. As on 31-03-2025, the company has a total of 58 Crore shares outstanding. Investment Rationale ADVERTISEMENT Aurobindo Pharma?s US sales growth (up 8.8% YoY to $470 million) in Q4FY25 was driven by gRevlimid; however, sales run-rate is likely to come down in FY26 as pricing competition intensifies, manufacturing at Pen-G plant has been temporarily halted due to fire in the coal yard near conveyor belt. However, production may resume soon post approval from Andhra Pradesh Pollution Control Board which the management expects in next couple of months. Europe business continues to grow at a faster pace and going ahead new launches may boost growth. Management expects traction in Europe to improve ahead led by new product launches and will launch biosimilars in Europe and UK in Q2FY26. Aurobindo has signed a definitive agreement with Merck Sharpe and Dohme (MSD Singapore) for contract manufacturing of innovative biologics, civil work on this plant is on and in FY27 it expects to commission this plant; revenue generation to start in FY28. ICICI Securities lowered its FY26/27E EBITDA by ~12%/8%, respectively, to factor in lower sales from Eugia. The stock currently trades at 17.1x FY26E and 14.3x FY27E earnings, and EV/EBITDA multiples of 9.1x FY26E and 7.6x FY27E. They have lowered rating on the stock to ADD (from Buy) with lower target price of Rs 1,330 (Rs 1,445 earlier), based on 16x FY27E EPS (18x FY26E EPS earlier). Key downside risks include regulatory hurdles, currency volatility and delay in US launches. Promoter/FII Holdings Promoters held 51.82 per cent stake in the company as of 31-Mar-2025, while FIIs owned 15.33 per cent, DIIs 26.23 per cent. (You can now subscribe to our ETMarkets WhatsApp channel) Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.
Economic Times
05-05-2025
- Business
- Economic Times
Indices: Stock market update: Nifty Pharma index advances 0.69%
ADVERTISEMENT ADVERTISEMENT ADVERTISEMENT NEW DELHI: The Nifty Pharma index closed on a positive note on of Biocon Ltd.(up 5.34 per cent), Aurobindo Pharma Ltd.(up 2.49 per cent), Glenmark Pharmaceuticals Ltd.(up 2.29 per cent), Natco Pharma Ltd.(up 1.76 per cent) and Lupin Ltd.(up 1.38 per cent) ended the day as top gainers in the the other hand, Dr. Reddy's Laboratories Ltd.(down 0.99 per cent), Laurus Labs Ltd.(down 0.45 per cent), J B Chemicals & Pharmaceuticals Ltd.(down 0.44 per cent) and Abbott India Ltd.(down 0.09 per cent) finished as the top losers of the Nifty Pharma index closed 0.69 per cent up at NSE Nifty50 index ended up 114.46 points at 24461.15, while the BSE Sensex stood up 294.85 points at the 50 stocks in the Nifty index, 38 ended in the green, while 12 closed in the of Vodafone Idea, YES Bank, Indian Oil Corp., Vishal Mega Mart and Swiggy were among the most traded shares on the of Godfrey Philips, Reliance Naval & Engg, Rajvir Ind, Synergy Green Ind and Navin Fluorine hit their fresh 52-week highs in today's trade, while Keerti Knowledge, GI Engineering, AGS Transact Tech, Globe Textiles(India)and Gensol Engg hit their fresh 52-week lows.
Time of India
05-05-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 0.39% in an upbeat market
NEW DELHI: The Nifty Pharma index traded positive around 10:04AM(IST)on Monday in an upbeat market. Biocon Ltd.(up 4.19 per cent), Aurobindo Pharma Ltd.(up 2.27 per cent), Natco Pharma Ltd.(up 1.62 per cent), Lupin Ltd.(up 1.6 per cent) and Laurus Labs Ltd.(up 1.04 per cent) were among the top gainers. Dr. Reddy's Laboratories Ltd.(down 0.6 per cent), J B Chemicals & Pharmaceuticals Ltd.(down 0.32 per cent), Mankind Pharma Ltd.(down 0.32 per cent), Sun Pharmaceutical Industries Ltd.(down 0.16 per cent) and Ipca Laboratories Ltd.(down 0.02 per cent) were the top losers on the index. The Nifty Pharma index was up 0.39 per cent at 21711.75 at the time of writing this report. Benchmark NSE Nifty50 index was up 132.46 points at 24479.15, while the BSE Sensex was up 428.75 points at 80930.74. Live Events Among the 50 stocks in the Nifty index, 40 were trading in the green, while 10 were in the red. Shares of Vodafone Idea, Indian Oil Corp., Vishal Mega Mart, YES Bank and Reliance Power were among the most traded shares on the NSE. Shares of Reliance Naval & Engg, Godfrey Philips, Force Motors, ARSS Infra and Anupam Rasayan India hit their fresh 52-week highs in today's trade, while Keerti Knowledge, CMI Ltd, AGS Transact Tech, Gensol Engg and Quintegra Sol hit fresh 52-week lows in trade.
Time of India
23-04-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 1.4%
NEW DELHI: The Nifty Pharma index closed on a positive note on Wednesday. Shares of Aurobindo Pharma Ltd.(up 4.98 per cent), Alkem Laboratories Ltd.(up 4.38 per cent), Torrent Pharmaceuticals Ltd.(up 2.65 per cent), Sun Pharmaceutical Industries Ltd.(up 2.37 per cent) and Lupin Ltd.(up 2.1 per cent) ended the day as top gainers in the pack. On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 4.26 per cent), Abbott India Ltd.(down 1.76 per cent), Mankind Pharma Ltd.(down 1.32 per cent) and Laurus Labs Ltd.(down 0.16 per cent) finished as the top losers of the day. The Nifty Pharma index closed 1.4 per cent up at 21738.95. Benchmark NSE Nifty50 index ended up 161.71 points at 24328.95, while the BSE Sensex stood up 520.9 points at 80116.49. Live Events Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. Shares of Vodafone Idea, Suzlon Energy, YES Bank, IDFC First Bank and Ola Electric Mobilit were among the most traded shares on the NSE. Shares of Country Condos, Choice Intnl, Rama Phosphates, Cura Tech and Paradeep Phosphates hit their fresh 52-week highs in today's trade, while AGS Transact Tech, Gensol Engg, Dhanvarsha Finvest, Punjab Alkalies and BDR Buildcon hit their fresh 52-week lows.
Yahoo
05-02-2025
- Business
- Yahoo
Proton Pump Inhibitors (PPIs) Market to Grow by USD 819.5 Million (2025-2029) with Drug Reformulation Boosting the Market, Report on How AI is Redefining Market Landscape
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global proton pump inhibitors (PPIs) market size is estimated to grow by USD 819.5 million from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Reformulation of drugs is driving market growth, with a trend towards growing geriatric population. However, increasing lawsuits against PPIs poses a challenge. Key market players include Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Proton Pump Inhibitors (PPIs) Market Scope Report Coverage Details Base year 2024 Historic period 2019 - 2023 Forecast period 2025-2029 Growth momentum & CAGR Accelerate at a CAGR of 4.7% Market growth 2025-2029 USD 819.5 million Market structure Fragmented YoY growth 2022-2023 (%) 4.4 Regional analysis North America, Europe, Asia, and Rest of World (ROW) Performing market contribution North America at 35% Key countries US, Germany, China, Canada, UK, India, France, Japan, Brazil, and UAE Key companies profiled Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd. Market Driver Proton Pump Inhibitors (PPIs) are popular acid-suppressing medications used to treat various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive issues. These medications work by reducing the production of stomach acid, targeting the gastric proton pump. The market for PPIs is on the rise due to an aging population, sedentary lifestyles, poor dietary choices, irregular eating patterns, stress, and obesity. Key players in the market include branded PPIs like Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole, as well as generic versions. Healthcare investment is booming in this area due to the growing demand for pharmaceutical solutions for gastrointestinal health. However, safety concerns and the availability of over-the-counter (OTC) drugs and hospital pharmacies present challenges for branded PPIs. The use of molecular biology, genomics, artificial intelligence, and big data analytics in the development of personalized medicine approaches is a trend in the industry. The World Health Organization has set guidelines for the use of PPIs, and regulatory bodies are closely monitoring safety concerns. The market is expected to grow significantly in the coming years due to increasing healthcare expenditure, a middle class with disposable incomes, and the availability of various drug formulations, including oral and injectable options. Direct-to-consumer advertising and the availability of PPIs in retail pharmacies and drug stores are also contributing to the market's growth. The aging population is a significant driver for the global Proton Pump Inhibitors (PPIs) market due to the increased prevalence of gastroesophageal reflux disease (GERD) and acidity with age. The esophageal sphincter, which prevents stomach acid from flowing back into the esophagus, weakens with age, leading to heartburn and acid reflux. Additionally, the digestive system slows down, further contributing to acidity. As the population ages, the incidence of these conditions is expected to rise, boosting market growth for PPIs. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Proton Pump Inhibitors (PPIs) market is witnessing significant growth due to the rising prevalence of acid-related disorders, particularly gastroesophageal reflux disease (GERD). Acid secretion is a natural process, but its excess can lead to conditions like peptic ulcers and acid reflux. PPIs inhibit the gastric proton pump, reducing stomach acid production. The market faces challenges from poor dietary choices, sedentary lifestyles, stress, and an aging population. Middle and upper-class populations with disposable incomes are major consumers, driving healthcare expenditure. Molecular biology, genomics, artificial intelligence, and big data analytics are transforming PPI development. Branded PPIs like Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole dominate the market, but safety concerns and generic versions pose challenges. The WHO recommends personalized medicine approaches for effective therapy. Dexlansoprazole is available in oral and injectable forms for various indications. Obesity, irregular eating patterns, and sedentary work cultures further fuel demand. Direct-to-consumer advertising and retail pharmacies/drug stores expand accessibility. Patents, hospital pharmacies, and OTC drugs also impact the market dynamics. Despite challenges, the future of PPIs lies in pharmaceutical solutions for gastrointestinal health. The Proton Pump Inhibitors (PPIs) market is currently facing legal challenges due to allegations that certain PPIs, such as PREVACID and DEXILANT, cause kidney injuries. Plaintiffs claim that manufacturers, including Takeda Pharmaceuticals, failed to adequately warn consumers about the potential risks. The FDA requested the withdrawal of all ranitidine products due to the potential formation of NDMA, a carcinogen, during storage and distribution. Other PPI manufacturers, including AstraZeneca, Pfizer, and Procter and Gamble, are also facing similar lawsuits. These developments may impact the market growth and consumer trust in PPIs. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This proton pump inhibitors (ppis) market report extensively covers market segmentation by Product Route Of Administration Geography 1.1 OTC PPIs- The over-the-counter (OTC) Proton Pump Inhibitors (PPIs) market has experienced significant growth in recent years due to the easy accessibility and affordability of these medications. OTC PPIs, such as PREVACID, NEXIUM, PRILOSEC, and Zegerid, are used for treating frequent heartburn by decreasing acid secretion in the stomach. Heartburn is a condition characterized by the backflow of stomach content into the esophagus, resulting in a burning sensation in the chest. OTC PPIs are intended for use for up to 14 days per year, according to the US Food and Drug Administration (FDA). The convenience of self-medication and cost savings associated with OTC PPIs have led to an increase in their usage. This trend is expected to continue, driving the growth of the OTC PPIs segment in the global Proton Pump Inhibitors market. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Proton Pump Inhibitors (PPIs) are a type of acid-suppressing medication widely used for managing various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other conditions where reducing stomach acid secretion is essential. These medications inhibit the gastric proton pump, thereby decreasing the production of stomach acid. PPIs are available in various drug formulations, including oral and injectable, and are used to treat both prescription and over-the-counter (OTC) indications. Lansoprazole, Esomeprazole, Rabeprazole, Pantoprazole, and Dexlansoprazole are some common PPIs. The market for PPIs is driven by the growing prevalence of acid-related disorders due to poor dietary choices, sedentary work cultures, stress, and aging population. Personalized medicine approaches are also being explored to optimize the use of PPIs and improve gastrointestinal health. The healthcare investment in pharmaceutical solutions for acid-related disorders continues to grow, making PPIs a significant market segment. Market Research Overview Proton Pump Inhibitors (PPIs) are a type of acid-suppressing medication widely used to manage various acid-related disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive issues. These medications work by inhibiting the gastric proton pump, which in turn reduces stomach acid production. PPIs have become increasingly popular due to the aging population, irregular eating patterns, sedentary lifestyles, stress, and poor dietary choices that contribute to acid reflux and other GI health problems. The market for PPIs is significant, driven by the middle class with disposable incomes and rising healthcare expenditure. Molecular biology, genomics, artificial intelligence, and big data analytics are transforming the development of personalized medicine approaches for PPIs. Safety concerns, patents, and the availability of generic versions also impact the market dynamics. Branded PPIs include Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole, and Pantoprazole, available in various formulations such as capsules, injectables, and OTC drugs. The market faces competition from hospital pharmacies, retail pharmacies, and drug stores. The World Health Organization the importance of addressing the global burden of acid-related disorders, making PPIs a crucial area of investment in pharmaceutical solutions. However, obesity and safety concerns remain significant challenges for the industry. Table of Contents: 1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation Product Route Of Administration Geography 7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@ View original content to download multimedia: SOURCE Technavio Sign in to access your portfolio
